From 1960 to the present, the regulatory burden, measured in paper, has gone from 20,000 pages of the Code of Federal Regulations (CFR) to 200,000 pages. Yesterday, the White House displayed stacks of paper with a stream of red tape across the symbolic decades of paper to make the case. Read More
Innovation in manufacturing requires investment. People, research, facilities and advanced technology are all key components that contribute to the next great breakthrough in products and processes. Manufacturers from every sector have driven innovation because they have placed a high priority on investing in these areas. In fact, manufacturers account for two-thirds of all private-sector investment in research and development. This has resulted in a competitive advantage for manufacturers in the United States allowing them to grow their business here and around the world. Read More
Today, the president issued an executive order to streamline the federal permitting approval process as a part of his infrastructure initiative. Specifically, the executive order will simplify the permitting process to provide for one federal decision that should be made within two years. The executive order establishing discipline and accountability in the environmental review and permitting process for infrastructure projects can be found here.
Manufacturers welcome today’s news and have long called for federal leadership in reducing excessive red tape in the environmental permitting process for infrastructure projects. Accountability and transparency for all permitting decisions are critical to achieving a set of best practices and certainty that will encourage additional private-sector investment and efficiency. Infrastructure should build in a period of a few years, not a decade.
A new Oliver Wyman report just released demonstrates the Health Insurance Tax (HIT) will result in higher health insurance premiums totaling $22 billion for more than 100 million Americans nationwide. This ACA tax will be paid by many, including those who are “fully insured,” meaning those employers who work directly with insurance brokers to purchase employee health plans. Even retirees who are accessing insurance through Medicare Advantage programs will be hit by the HIT.
For manufacturers who are fully insured and those purchasing individual plans, this tax only adds to rising costs and higher premiums. Joe Eddy, president and CEO of Eagle Manufacturing, told his story before the House Education and the Workforce Committee earlier this year. He explained the ACA taxes and compliance burdens “have been costly, disruptive and distracting from the things we are good at doing as manufacturers.”
According to the Oliver Wyman report summarized here, the HIT could raise the cost of premiums by an additional $540 for employees’ families receiving health benefits from fully insured larger employers. Small business owners and their employees could shoulder an additional $500 for family coverage as a result of the HIT. These cost increases are preventable if Congress acts. Manufacturers provide competitive health benefits to attract and maintain skilled employees and because manufacturers know it’s the right thing to do. Congress should be making it easier to provide insurance, not more difficult.
Regrettably, it’s not just the HIT. The medical device tax—another tax that discourages innovation, growth and job creation—is ready to go into effect next year. In 2015, a temporary suspension of the 2.3 percent excise tax on medical device manufacturers was enacted after 29,000 jobs were lost as a result of the misguided tax. However, that two-year relief runs out at the end of 2017, making full repeal of this tax critical to manufacturers of medical devices. Manufacturers support immediate action to permanently repeal the medical device tax to prevent this tax from eliminating jobs and hurting local economies in all 50 states.
It was unfortunate that the Senate did not pass major health care reform legislation in July, but manufacturers urge the Senate not to give up efforts. Both the House and Senate must advance opportunities to address the burdensome taxes associated with the ACA because the deadlines are around the corner and the clock is ticking.
This morning, the Senate is voting on H.R. 2430, the Food and Drug Administration Reauthorization Act of 2017 (FDARA), hopefully with the affirmative action of sending the bill to President Donald Trump’s desk. The bill was passed by the House of Representatives with overwhelming bipartisan support in July.
As noted in a National Association of Manufacturers’ letter to the Senate, “FDARA is the ultimate public–private partnership that supports patients who need lifesaving medical treatments while promoting science, research and technological innovation.”
Manufacturers in America lead the nation in research and development (R&D), driving more innovation than any other sector. Pharmaceutical manufacturers, in particular, account for nearly one-third of all manufacturing R&D. In turn, the United States is a global leader in the development of medical breakthroughs.
Reauthorization of the FDA’s user-fee program would support the research pipeline and accelerate the development of new medicines and treatments. The NAM supports the Senate’s effort to act quickly in voting to reauthorize FDARA as it stands before adjourning for recess. Any delay to this critical legislation would jeopardize America’s position as a global leader in medical discovery.
Efforts to stop the impacts of the onerous Health Insurance Tax (HIT) must continue as the Senate debates health care legislation. This $100 billion tax levied on fully insured health plans is paid by consumers and, if left unaddressed, will be a shock to retirees on Medicare Advantage and Part D plans as well as employers, individuals and families who purchase off-the-shelf health care plans. That tax will go into effect next year.
Manufacturers are fully behind repealing the “Cadillac” tax, the medical device tax, the health insurance tax and the pharmaceutical tax as well as reducing the burden of the employer mandate. The National Association of Manufacturers sent a key-vote letter to the Senate on Wednesday in support of Amendment 271 to underscore the importance of action on these issues. Unfortunately, the amendment failed in a 45–55 vote.
A full repeal of the Affordable Care Act (ACA) will help employers contain rising health care costs and provide much-needed predictability so that manufacturers can continue providing quality health care to employees. Manufacturers encourage the Senate to unlock the stranglehold of the ACA on manufacturers.